Aeterna Zentaris Gmbh

Zentaris Gmbh

Zentaris Ag

Ziopharm Oncology, Inc.

Æterna Zentaris Gmbh

Zentaris Ivf Gmbh

Jürgen Engel

Dieter Sauerbier

Thomas Reissmann

Burkhard Wichert

Eckhard Günther

Herbert Sindermann

Thomas Beckers

Peter Emig

Bernd Nickel

Thomas Klenner

Werner Sarlikiotis

Matthias Rischer

Gerald Bacher

Horst Bauer

Babette Aicher

Daniel Perrissoud

Karl Werner

Erik Bruyneel

Kirsten Peters

Oliver Bauer

Dominique Di Stefano

Frank Güthlein

Rainer Voegeli

Günter Kamp

Gudrun Sauerbier, Legal Representative

Mathias Pietras

Horst Müller

LHRH analogs and LHRH antagonists for use in the treatment or prophylaxis of hormone-dependent cancers, in particular prostate cancer, prostate carcinoma and/or advanced prostate carcinoma, by administering an initial dose of an LHRH analog over a first period sufficient to effect hormonal castration, then administering a maintenance dose of an LHRH antagonist over a second period, the dose being insufficient to achieve and/or maintain hormonal castration.

Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits

The invention relates to the use of alkylphosphocholines in combination with antitumor medicaments for the treatment of benign and malignant oncoses in humans and animals. It is possible in this connection for the alkylphosphocholines to be employed in a combination according to the invention with one or a combination of various approved cytostatics. Preferred alkylphosphocholines are described by the Formula II. 

Use of alkylphosphocholines in combination with antitumor medications for the treatment of benign and malignant oncoses in humans and mammals

The invention relates to the use of alkylphosphocholines in combination with antimetabolites for the treatment of multiple myeloma, colon cancer or renal cancer. Preferred alkylphosphocholines are described by the Formula II.  A particularly effective treatment includes administering a combination of perifosine and capecitabine.

Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals

A process for preventing a protozoal disease by the administration of an alkyl phosphocholine to a human being.

Process for preventing protozoal diseases

A novel lyophilizate and method of preparation as well as the use of the lyophilizate to treat female infertility and for gonad protection. Cetrorelix is dissolved in acetic acid 30% v/v, the solution is transferred to water and freeze dried.

Oligopeptide lyophilisate, their preparation and use

The invention relates to the use of N-substituted indole-3-glyoxylamides of the general Formula I: and to pharmaceutical compositions having antitumor action.

Indolyl-3-glyoxylic acid derivatives having therapeutically valuable properties

The present invention relates to the treatment of dementia and neurodegenerative diseases like Alzheimer's disease with intermediate doses of LHRH antagonists which do not cause a castration. A preferred LHRH antagonist is cetrorelix.

Treatment of dementia and neurodegenerative diseases with intermediate doses of LHRH antagonists

An aqueous injectable soution of an LHRH antagonist, such as Cetrorelix, in an organic, pharmaceutically acceptable acid, such as gluconic acid.

Injectable solution of an LHRH antagonist

A lyophilizate, method of preparation, and use of the lyophilizate for gonad protection is described. The lyophilizate comprises cetrorelix dissolved in 30% (v/v) acetic acid, transferred to water, and freeze-dried.

Preparation and use of oligopeptide lyophilisate for gonad protection

Growing community of inventors

Alzenau, Germany

Jürgen Engel